Is There an Increased Risk of ALL in Patients with First Cancers Treated with Radiotherapy and/or Chemotherapy?

ConclusionAmong patients treated for a first cancer, receipt of RT and/or CT was associated with higher relative risks and hazards for developing ALL than those not receiving cytotoxic modalities. Patients with hematologic first cancers (myeloid lineage or plasma cell dyscrasias) had the highest hazards of developing ALL as second cancer. When considering the risk kinetics and subgroup analyses in patients with solid first cancers, RT only or RT + CT, but not CT only, associate with increased risks for ALL. To our knowledge this is the largest evaluation of the risk of ALL in cancer patients treated with various modalities. Differentially elevated risks of ALL observed in cancer cohorts based on the treatment modality that was received for a prior cancer suggests a possible biological mechanism that needs to be explored further.DisclosuresGerds: Celgene: Consultancy; CTI Biopharma: Consultancy; Apexx Oncology: Consultancy; Incyte: Consultancy. Nazha: MEI: Consultancy. Carraway: Jazz: Speakers Bureau; Amgen: Membership on an entity's Board of Directors or advisory committees; Agios: Consultancy, Speakers Bureau; Balaxa: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; FibroGen: Consultancy; Novartis: Speakers Bureau; Celgene: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau. Majhail: Incyte: Honoraria; Anthem, Inc.: Consultancy; Atara: Honoraria. Maciejewski: Apellis Pharmaceuticals: Con...
Source: Blood - Category: Hematology Authors: Tags: 612. Acute Lymphoblastic Leukemia: Clinical Studies: Improving Outcomes with Cellular Therapy Source Type: research